Viktor Drvota

Viktor Drvota is the current Chief Executive Officer at Karolinska Development. Prior to this, they served as a Board Member at ClanoTech AB from March 2016 to July 2016, Forendo Pharma Ltd from September 2017 to December 2021, Aprea Therapeutics AB from April 2017 to April 2019, and Promimic AB from April 2016 to April 2018. Viktor also served as the Chairman of the Board of Directors at Modus Therapeutics AB.

Drvota has extensive experience in the medical field, particularly in ophthalmology and womens health. Viktor has played an integral role in the development and sale of several assets, most notably Clanotech's lead candidate, an inhibitor of the alpha5beta1-integrin receptor, which was sold to Rosetta capital, and Forendo Pharma Ltd, which was sold to Organon for a total deal value of 950 MUSD.

Drvota is a highly accomplished individual with a proven track record of success in the medical field. Viktor will no doubt continue to be a driving force in the advancement of medical technologies and treatments in the years to come.

Viktor Drvota's educational career includes earning a Doctor of Medicine (M.D.) from the Karolinska Institutet, as well as a Doctor of Philosophy - PhD in Internal medicine from the same school. Viktor is also an Associate professor in the field of Cardiology at Karolinska Institutet. In addition, they have completed a Specialist training in Interventional Cardiology Residency Program at Karolinska Institutet.

Fredrik Järrsten - Chief Financial Officer, Johan Dighed - General Counsel, and Elisabet Gimbringer - Financial Manager report to Viktor Drvota.